These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 8843969)
1. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma. Rudolf Z; Strojan P Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969 [TBL] [Abstract][Full Text] [Related]
2. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G; Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225 [TBL] [Abstract][Full Text] [Related]
4. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614 [TBL] [Abstract][Full Text] [Related]
5. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma]. Kretschmer L; Helmbold P; Emmert S; Marsch WC Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468 [TBL] [Abstract][Full Text] [Related]
6. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma]. Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103 [TBL] [Abstract][Full Text] [Related]
7. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499 [TBL] [Abstract][Full Text] [Related]
8. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Pritchard KI; Quirt IC; Cowan DH; Osoba D; Kutas GJ Cancer Treat Rep; 1980; 64(10-11):1123-6. PubMed ID: 7459898 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha. Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285 [TBL] [Abstract][Full Text] [Related]
10. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. Cocconi G; Bella M; Calabresi F; Tonato M; Canaletti R; Boni C; Buzzi F; Ceci G; Corgna E; Costa P N Engl J Med; 1992 Aug; 327(8):516-23. PubMed ID: 1635566 [TBL] [Abstract][Full Text] [Related]
11. Influence of therapy on the antioxidant status in patients with melanoma. Gadjeva V; Dimov A; Georgieva N J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287 [TBL] [Abstract][Full Text] [Related]
13. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884 [TBL] [Abstract][Full Text] [Related]
14. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma]. Gershanovich ML; Akimov MA Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220 [TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma. Tan EH; Ang PT Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255 [TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444 [TBL] [Abstract][Full Text] [Related]
17. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. Serrone L; Zeuli M; Sega FM; Cognetti F J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932 [TBL] [Abstract][Full Text] [Related]
18. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149 [TBL] [Abstract][Full Text] [Related]
19. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma]. Célérier P; Dreno B; Bureau B; Litoux P Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787 [TBL] [Abstract][Full Text] [Related]
20. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]